CVS Health Corp (CVS) delivered a solid quarter Tuesday that should ease some investor nerves heading into 2026. The healthcare giant posted sales of $105.69 billion, comfortably ahead of the $103.59 billion consensus estimate. Adjusted earnings came in at $1.09 per share, beating the 99-cent estimate even as they declined from $1.19 in the prior year.
More importantly, CVS stood by its fiscal 2026 adjusted earnings guidance of $7.00-$7.20 per share, right in line with the Street consensus of $7.17. Management described the guidance as highlighting "our strong position for 2026," which is corporate-speak for "we've got this under control."
The company did adjust its cash flow expectations, lowering its fiscal 2026 operations guidance to at least $9.0 billion from at least $10.0 billion. Revenue guidance sits at a minimum of $400 billion versus consensus of $409.77 billion, with adjusted operating income expected between $15.07 billion and $15.41 billion.
Why Analysts Aren't Worried
Bank of America Securities views the reaffirmed guidance as genuinely positive, especially given the anxiety swirling around Medicare Advantage headwinds in 2027 and increased regulatory scrutiny facing pharmacy benefit managers. The firm sees CVS armed with multiple growth levers across its business segments.
In Pharmacy & Consumer Wellness, the Rite Aid store acquisitions and competitive challenges hitting industry peers should support flat earnings growth near term. Over in Health Care Benefits, group Medicare Advantage rate renewals represent what analyst Allen Lutz calls "low-hanging fruit" for margin improvement, complemented by continued progress in Individual Medicare Advantage margins.
Lutz noted Wednesday that CVS has several tools to counter headwinds from the 2027 preliminary rate notice, including future share buybacks and additional Group Medicare Advantage repricing opportunities.
The Health Services segment also offers upside. Bank of America expects continued margin improvement at Oak Street Health as clinic closures, fewer new locations, and expanding patient panels create a path toward break-even profitability.
Bottom line: Bank of America remains bullish on CVS's long-term strategy, maintaining its Buy rating with a $95 price target. CVS shares traded up 0.87% at $76.36 Wednesday.
